Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

HORIZONS-AMI (Stone), 2008 - bivalirudin vs Heparin plus GP IIb/IIIa inhibitor

ISAR-REACT 3, 2008 - bivalirudin vs UFH

Hull, 2006 - extended tinzaparin vs vitamin K antagonist

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

Deitcher, 2006 - extended enoxaparin vs warfarin

ACUITY (Stone) (bivalirudin alone), 2006 - bivalirudin vs heparin + anti Gp2b3a

STEEPLE, 2006 - enoxaparin vs UFH

EVET, 2005 - enoxaparin vs tinzaparin

Wells (subgroup), 2005 - tinzaparin+warfarin vs dalteparin+warfarin

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

Chong, 2005 - LMWH at home vs UFH in hospital

REPLACE-1, 2004 - bivalirudin vs UFH

Ramacciotti, 2004 - LMWH at home vs UFH in hospital

Cesarone, 2003 - extended enoxaparin vs coumadin

CRUISE, 2003 - Enoxaparin vs UFH

Natarajan (+ antiGp2b3a), 2003 - Dalteparin vs UFH + anti Gp2b3a

Lee, 2003 - extended dalteparin vs

THE-PRINCE (Kleber), 2003 - enoxaparin vs UFH

REPLACE-2, 2003 - bivalirudin vs hepatin + anti Gp2b3a

Natarajan (without antiGp2b3a), 2003 - Dalteparin vs UFH

Kleiman, 2002 - bivalirudin + eptifibatide vs heparin + eptifibatide

Meyer, 2002 - extended enoxaparin vs warfarin

Merli sub group, 2001 - Enoxaparin vs unfractioned heparin

Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH

Dubek b (+abciximal), 2001 - Enoxaparin+abciximab vs UFH



See also:

  • All DVT prophylaxis clinical trials
  • All clinical trials of LMWH
  • All clinical trials of Enoxaparin
    		•  

    ENOXACAN study, 1997

    Treatments

    Studied treatment Enoxaparin 4000 anti Xa units
    Control treatment UFH 15 000 units

    Patients

    Patients Abdominopelvic surgery
    Baseline characteristics
    cancer surgery (%) 100% 

    Method and design

    Randomized effectives 555 / 560 (studied vs. control)
    Blinding Blind


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Symptomatic pulmonary embolism

    0 / 555
         2 / 560
         classic 0,11 [0,00;6,97]

    All cause death

    26 / 555
         34 / 560
         0,77 [0,47;1,27]

    Bleeding

    104 / 555
         96 / 560
         1,09 [0,85;1,41]

    asymptomatic DVT

    45 / 312
         58 / 319
         0,79 [0,56;1,13]

    Symptomatic venous thromboembolism (DVT, PE)

    4 / -9
         6 / -9
         classic 0,67 [0,14;3,19]

    Major bleeding

    23 / 555
         16 / 560
         classic 1,45 [0,77;2,72]

    wound haematoma / infection

    284 / -9
         242 / -9
         classic 1,17 [0,46;3,00]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Symptomatic pulmonary embolism 0 / 555 (0,1%) 2 / 560 (0,4%) 0,25 [0,01;5,58]    
    All cause death 26 / 555 (4,7%) 34 / 560 (6,1%) 0,77 [0,47;1,27]    
    Bleeding 104 / 555 (18,7%) 96 / 560 (17,1%) 1,09 [0,85;1,41]    
    asymptomatic DVT 45 / 312 (14,4%) 58 / 319 (18,2%) 0,79 [0,56;1,13]    
    Major bleeding 23 / 555 (4,1%) 16 / 560 (2,9%) 1,45 [0,77;2,72]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 4,68% 6,07% -13,9‰
    Bleeding 18,74% 17,14% 1,6%
    asymptomatic DVT 14,42% 18,18% -37,6‰
    Major bleeding 4,14% 2,86% 1,3%


    Reference(s)

    Trials register # NA

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend